Cerus Corp. (CERS)

6.63
NASDAQ : Health Technology
Prev Close 6.77
Day Low/High 6.61 / 6.87
52 Wk Low/High 2.75 / 8.05
Avg Volume 829.10K
Exchange NASDAQ
Shares Outstanding 133.81M
Market Cap 905.92M
EPS -0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Dr. Laurence Corash Recognized With The Prestigious Dale A. Smith Memorial Award

Dr. Laurence Corash Recognized With The Prestigious Dale A. Smith Memorial Award

Cerus Corporation (Nasdaq: CERS) today announced Dr. Laurence Corash, the Company's co-founder and chief scientific officer has been awarded the prestigious Dale A.

Notable Two Hundred Day Moving Average Cross - CERS

Notable Two Hundred Day Moving Average Cross - CERS

In trading on Wednesday, shares of Cerus Corp. crossed below their 200 day moving average of $5.96, changing hands as low as $5.90 per share.

Cerus Appoints Eric Bjerkholt To Board Of Directors

Cerus Appoints Eric Bjerkholt To Board Of Directors

Cerus Corporation (Nasdaq: CERS) today announced the appointment of Eric Bjerkholt to its Board of Directors.

Cerus Enters Oversold Territory (CERS)

Cerus Enters Oversold Territory (CERS)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Cerus To Host Institutional Investor Meeting

Cerus To Host Institutional Investor Meeting

Cerus Corporation (Nasdaq: CERS) today announced that it will host an Institutional Investor Meeting on Tuesday, October 16, 2018 in Boston, Massachusetts.

Cerus To Present At The Cantor Fitzgerald 2018 Global Healthcare Conference

Cerus To Present At The Cantor Fitzgerald 2018 Global Healthcare Conference

Cerus Corporation (Nasdaq: CERS) today announced that William 'Obi' Greenman, Cerus' president and chief executive officer, will present and provide a corporate update at the Cantor Fitzgerald 2018 Global Healthcare Conference in New York City on Tuesday,...

Cerus Appoints Timothy L. Moore To Board Of Directors

Cerus Appoints Timothy L. Moore To Board Of Directors

Cerus Corporation (Nasdaq:CERS) today announced the appointment of Timothy L. Moore to its Board of Directors.

Cerus To Present At The Baird 2018 Global Healthcare Conference

Cerus To Present At The Baird 2018 Global Healthcare Conference

Cerus Corporation (Nasdaq: CERS) today announced that Kevin D. Green, Cerus' vice president, finance and chief financial officer, will present and provide a corporate update at the Baird 2018 Global Healthcare Conference in New York City on Thursday,...

Cerus Corporation Reports Second Quarter 2018 Results

Cerus Corporation Reports Second Quarter 2018 Results

Cerus Corporation (Nasdaq: CERS) announced today financial results for the second quarter ended June 30, 2018, and raised its full year guidance for product revenue.

Cerus To Release Second Quarter 2018 Results On August 2, 2018

Cerus To Release Second Quarter 2018 Results On August 2, 2018

Cerus Corporation (Nasdaq:CERS) announced today that its second quarter results will be released on Thursday, August 2, 2018, after the close of the stock market.

New Navy Policy Implements Full Adoption Of Pathogen-Reduced Apheresis Platelets Collected At U.S. Navy Blood Donor Centers

New Navy Policy Implements Full Adoption Of Pathogen-Reduced Apheresis Platelets Collected At U.S. Navy Blood Donor Centers

Cerus Corporation (Nasdaq: CERS) announced today that the U.S.

First Week Of CERS February 2019 Options Trading

First Week Of CERS February 2019 Options Trading

Investors in Cerus Corp. saw new options become available this week, for the February 2019 expiration.

Cerus Presents Results Of European Phase 3 Chronic Anemia Study At The 23rd Congress Of European Hematology Association

Cerus Presents Results Of European Phase 3 Chronic Anemia Study At The 23rd Congress Of European Hematology Association

Cerus Corporation (Nasdaq: CERS) announced that results from SPARC, the Company's European Phase 3 study evaluating the efficacy and safety of INTERCEPT-treated red blood cells (RBCs) in thalassemia major patients, were presented today at the 23 rd...

Cerus Announces Presentations Highlighting INTERCEPT Blood Systems At The 35th International Congress Of The International Society Of Blood Transfusion

Cerus Announces Presentations Highlighting INTERCEPT Blood Systems At The 35th International Congress Of The International Society Of Blood Transfusion

Cerus Corporation (Nasdaq: CERS) today announced that it will make multiple presentations, including two oral abstracts, that will be featured at the 35 th International Congress of the International Society of Blood Transfusion (ISBT) in Toronto, Canada...

Cerus Announces Additional BARDA Funding To Support Development Of INTERCEPT Blood System For Red Blood Cells

Cerus Announces Additional BARDA Funding To Support Development Of INTERCEPT Blood System For Red Blood Cells

Cerus Corporation (Nasdaq: CERS) today announced an amendment to the Company's contract with the Biomedical Advanced Research and Development Authority (BARDA).

Cerus Corporation Reports First Quarter 2018 Results

Cerus Corporation Reports First Quarter 2018 Results

Cerus Corporation (Nasdaq:CERS) announced today financial results for the first quarter ended March 31, 2018, and raised its full year guidance for product revenue.

Cerus To Present At The Deutsche Bank 43rd Annual Health Care Conference On Wednesday May 9, 2018

Cerus To Present At The Deutsche Bank 43rd Annual Health Care Conference On Wednesday May 9, 2018

Cerus Corporation (Nasdaq: CERS) announced today that Dr. Laurence M.

Cerus Announces Health Canada Approval Of The INTERCEPT Blood System For Platelets

Cerus Announces Health Canada Approval Of The INTERCEPT Blood System For Platelets

Cerus Corporation (Nasdaq: CERS) announced today that Health Canada has approved the commercialization of INTERCEPT Blood System for platelets.

Cerus To Release First Quarter 2018 Results On May 8, 2018

Cerus To Release First Quarter 2018 Results On May 8, 2018

Cerus Corporation (Nasdaq:CERS) announced today that its first quarter results will be released on Tuesday, May 8, 2018, after the close of the stock market.

Cerus' RedeS Phase 3 Red Blood Cell Study Expands Into The Continental U.S.

Cerus' RedeS Phase 3 Red Blood Cell Study Expands Into The Continental U.S.

Cerus Corporation (NASDAQ: CERS) announced today that Baylor St. Luke's Medical Center in Houston became the first center in the continental U.

Small-Cap Stocks Are Doing Something They Haven't Done Consistently in 3 Years

Small-Cap Stocks Are Doing Something They Haven't Done Consistently in 3 Years

Small-cap stocks have finally jumped back to life on prospects for a strong U.S. economy this year. What trade war?

Cerus Announces The Fourth Biologics License Application (BLA) Approval For A U.S. Blood Center Customer

Cerus Announces The Fourth Biologics License Application (BLA) Approval For A U.S. Blood Center Customer

Cerus Corporation (NASDAQ: CERS) announced today that The Community Blood Center (CBC) of Appleton, Wisconsin received approval by the U.

Cerus Corporation Reports Record Fourth Quarter And Year End 2017 Results

Cerus Corporation Reports Record Fourth Quarter And Year End 2017 Results

Cerus Corporation (Nasdaq: CERS) today announced financial results for the fourth quarter and year ended December 31, 2017.

Cerus To Present At The Cowen And Company 38th Annual Health Care Conference On March 13, 2018

Cerus To Present At The Cowen And Company 38th Annual Health Care Conference On March 13, 2018

Cerus Corporation (NASDAQ: CERS) announced today that William 'Obi' Greenman, Cerus' president and chief executive officer, is scheduled to present a corporate update at the Cowen and Company 38th Annual Health Care...

Cerus To Release Fourth Quarter And Year End 2017 Results On March 8, 2018

Cerus To Release Fourth Quarter And Year End 2017 Results On March 8, 2018

Cerus Corporation (NASDAQ:CERS) announced today that its fourth quarter and year end results for 2017 will be released on Thursday, March 8, 2018, after the close of the stock market.

Cerus Announces Closing Of Public Offering Of Common Stock And Full Exercise Of The Underwriter's Option To Purchase Additional Shares

Cerus Announces Closing Of Public Offering Of Common Stock And Full Exercise Of The Underwriter's Option To Purchase Additional Shares

Cerus Corporation (NASDAQ:CERS) today announced the closing of a registered underwritten public offering of its common stock, which included the sale of additional shares of common stock upon full exercise of the...

Cerus Announces Pricing Of Public Offering Of Common Stock

Cerus Announces Pricing Of Public Offering Of Common Stock

Cerus Corporation (NASDAQ:CERS) today announced the pricing of a registered underwritten public offering of its common stock for proceeds of $50.

Cerus Announces Public Offering Of Common Stock

Cerus Announces Public Offering Of Common Stock

Cerus Corporation (NASDAQ: CERS) today announced that it has commenced a registered underwritten public offering of $50.

TheStreet Quant Rating: D- (Sell)